Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023

JAMA. 2024 Jun 18;331(23):2041-2043. doi: 10.1001/jama.2024.7112.

Authors

Joyce M Lee¹, Mona Sharifi², Lauren Oshman³, Dina H Griauzde⁴, Kao-Ping Chua¹

Affiliations

¹ Susan B. Meister Child Health Evaluation and Research Center, University of Michigan Medical School, Ann Arbor.
² Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut.
³ Department of Family Medicine, University of Michigan Medical School, Ann Arbor.
⁴ Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.

No abstract available

Plain language summary

This study uses data from US retail pharmacies to assess national GLP-1RA dispensing to adolescents and young adults from 2020-2023.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Anti-Obesity Agents / administration & dosage
Anti-Obesity Agents / supply & distribution
Anti-Obesity Agents / therapeutic use
Child
Diabetes Mellitus, Type 2* / drug therapy
Drug Prescriptions* / statistics & numerical data
Female
Glucagon-Like Peptide-1 Receptor / agonists
Glucagon-Like Peptide-1 Receptor Agonists* / administration & dosage
Glucagon-Like Peptide-1 Receptor Agonists* / supply & distribution
Glucagon-Like Peptide-1 Receptor Agonists* / therapeutic use
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / supply & distribution
Hypoglycemic Agents / therapeutic use
Male
Obesity* / drug therapy
United States / epidemiology
United States Food and Drug Administration
Young Adult

Substances

Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents
Anti-Obesity Agents

Grants and funding